Human SIRPα transgenic mice and their methods of use

Patent metadata

Field	Value
Publication number	US-9839208-B2
Application number	US-201615223879-A
Country	US
Kind code	B2
Filing date	Jul 29, 2016
Priority date	Sep 20, 2010
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

Abstract

The invention relates generally to compositions and methods of using transgenic non-human animals expressing human SIRPα that are engrafted with a human hematopoietic system. In various embodiments, the human hematopoietic system engrafted, human SIRPα transgenic non-human animals of the invention are useful as systems for the in vivo evaluation of the growth and differentiation of hematopoietic and immune cells, for the in vivo assessment of an immune response, for the in vivo evaluation of vaccines and vaccination regimens, for in vivo production and collection of immune mediators, including human antibodies, and for use in testing the effect of agents that modulate hematopoietic and immune cell function.

First claim

The invention claimed is:

1. A transgenic immunodeficient mouse having a genome comprising a nucleic acid encoding human signal regulatory protein alpha (SIRPα) operably linked to a SIRPα promoter, wherein the mouse expresses the human SIRPα.

2. The transgenic immunodeficient mouse of claim 1 , wherein the mouse does not express recombination activating gene 2 (Rag-2 −/− ).

3. The transgenic immunodeficient mouse of claim 1 , wherein the mouse does not express IL2 receptor gamma chain (gamma chain −/− ).

4. The transgenic immunodeficient of claim 1 , wherein the mouse does not express Rag-2 or IL2 receptor gamma chain (Rag-2 −/− gamma chain −/− ).

5. The transgenic mouse of claim 1 , further comprising human hematopoietic stem and progenitor cells (HSPCs).

6. The transgenic mouse of claim 1 , further comprising the progeny of HSPCs.

7. A method of engraftment of a human hematopoietic stem and progenitor cell (HSPC) into a transgenic immunodeficient mouse comprising engrafting a human HSPC into the transgenic immunodeficient mouse of claim 1 .

8. The method of claim 7 , wherein the transgenic immunodeficient mouse does not express recombination activating gene 2 (Rag-2 −/− ).

9. The method of claim 7 , wherein the transgenic immunodeficient mouse does not express endogenous IL2 receptor (gamma chain −/− ).

10. The method of claim 7 , wherein the transgenic immunodeficient mouse animal does not express endogenous Rag-2 or gamma chain (Rag-2 −/− gamma chain −/− ).

11. A method of producing a human antibody from a SIRPα transgenic immunodeficient mouse, said method comprising: a) administering at least one human HSPC to a SIRPα transgenic immunodeficient mouse to generate a human hematopoietic system engrafted transgenic mouse, b) subsequently contacting said engrafted transgenic mouse with at least one antigen, c) collecting from said engrafted transgenic mouse at least one human cell producing at least one human antibody that binds to said antigen, and d) isolating said antibody from the at least one antibody producing cell.

12. The method of claim 11 , wherein the antibody is a monoclonal antibody.

13. The method of claim 11 , wherein the engrafted mouse is a +huSIRPα, Rag-2 −/− , gamma chain −/− mouse.

14. The method of claim 11 , wherein the at least one human HSPC is a CD34+ cell obtained from at least one selected from the group consisting of: human fetal liver, bone marrow, cord blood, peripheral blood, or spleen.

15. The method of claim 11 , wherein said antibody producing cell is a human B-cell.

16. The method of claim 11 , wherein the antigen is at least one selected from the group consisting of: a peptide, a polypeptide, an MHC/peptide complex, DNA, a live virus, a dead virus or portion thereof, a live bacteria, a dead bacteria or portion thereof, and a cancer cell or portion thereof.

17. The method of claim 11 , wherein the at least one collected antibody producing cell is selected from the group consisting of: a human CD19+ cell, a human CD20+ cell, a human CD22+ cell, and a human CD27+ cell.

Assignees

• Univ Yale

Inventors

• Flavell Richard A
• Strowig Till
• Eynon Elizabeth
• Philbrick William
• Manz Markus

Classifications

• C07K16/2803

  against the immunoglobulin superfamily · CPC title

• A01K2227/105

  Murine · CPC title

• A01K2207/12

  Animals modified by administration of exogenous cells · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• A01K2217/072

  maintaining or altering function, i.e. knock in · CPC title